Networking Breakfast :: Jeffrey Young, CFO, OvaScience

 

 

Thursday, March 17, 2016
7:00am - 9:00am
Serafina Boston
10 High St.| Boston, MA

 

Members: 65.00 (75 after 03/10)
Young Professional Members: 50.00
Non-Members: 105.00 (115 after 03/10)

 

Join ACG Boston and New England's deal professionals for March's Networking Breakfast, where New England's M&A community comes together to network and hear high caliber industry experts share their outlook, opinions, successes and failures in M&A.

 

March's Networking Breakfast features Jeffrey Young, Chief Financial Officer, OvaScience. Mr. Young joined OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions. Prior to Transmedics, Mr. Young was CFO and Treasurer at Lantheus Medical Imaging, Inc. While at Lantheus, an international corporation, he was responsible for multiple functions, including finance, accounting, customer service, tax and treasury. He also assisted in raising 400 million in a registered notes offering. Before Lantheus, Mr. Young served as Chief Accounting Officer, Vice President of Finance and Treasurer at Critical Therapeutics, and managed the company’s transition during its acquisition by Cornerstone BioPharma. Earlier in his career, Mr. Young held finance roles at PerkinElmer, Inc. and PricewaterhouseCoopers.

Mr. Young is a Certified Public Accountant and holds a B.S. in Business Administration from Georgetown University.

OvaScience is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience has commenced a non-commercial preceptorship program with OvaPrimeSM treatment, which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the United States.